Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardioLogical Solutions: Combining Forces To Deliver A Range Of TAVI Accessories

Executive Summary

The recently announced merger of two innovative cardiovascular device companies – VasoStitch Inc. and Emboline Inc. – under the name CardioLogical Solutions promises to create a full range of accessory devices to improve the safety and efficacy of transcatheter aortic valve implantation (TAVI) procedures performed by either an interventional cardiologist or a thoracic surgeon.

You may also be interested in...



TAVR Emerging As Next Big Application For Embolic Protection Devices

Studies suggest transcatheter aortic valve replacement is associated with a higher stroke risk than standard surgical valve replacement, presumably due to embolic debris released during the TAVR procedure. To address this concern, several companies are developing TAVR-specific embolic protection devices, and their success may prove to be a key driver of future growth in this $1+ billion market.

Research in Brief

Neuronetics releases long-term data on NeuroStar TMS therapy for depression. Bayesian methods confirm stenting matches surgery in patients with unprotected left-main disease. More research briefs.

Expanding The EVAR Toolbox: A Glimpse Into The Future

The US endovascular abdominal aortic aneurysm repair (EVAR) market is one of the most dynamic device segments in the interventional arena, with growth and innovation driven in large part by an accelerating effort to expand EVAR to a wider patient pool. This movement toward more challenging cases does have a downside in terms of potential complications and uncertain long-term durability as physicians push the envelope of existing technology. However, innovation in this field is continuing at a fairly steady pace, and several important new technologies that could improve the safety and durability of EVAR in more complex anatomy could be introduced in the near future. If these devices live up to their early promise, they are likely to ignite even stronger growth in a market already valued at over $1 billion annually worldwide.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT035608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel